Sarepta Therapeutics Announces Positive Results in Its Study Evaluating Gene Expression, Dystrophin Production, and Dystrophin Localization in Patients with Duchenne Muscular Dystrophy (DMD) Amenable
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/12/2026
Go back to Sarepta Therapeutics Announces Positive Results in Its Study Evaluating Gene Expression, Dystrophin Production, and Dystrophin Localization in Patients with Duchenne Muscular Dystrophy (DMD) Amenable
September 6, 2017 11:54 AM EDT
SunTrust Robinson Humphrey analyst Edward Nash reiterated a Buy rating and $56 price target on Sarepta Therapeutics (NASDAQ: SRPT) after the company announced positive muscle biopsy results from the Phase I/II 4053-101 study that evaluated golodirsen (SRP-4053) for the treatment of DMD patients... More
September 6, 2017 11:06 AM EDT
William Blair analyst Tim Lugo weighed in on Sarepta Therapeutics (NASDAQ: SRPT) after the company announced positive interim 48-week data from its ongoing European Phase I/II study for DMD patients amenable to skipping exon 53 with golodirsen (SRP-4053).
Lugo notes all... More
September 6, 2017 10:57 AM EDT
(Updated - September 6, 2017 11:00 AM EDT)
(updated to add analyst comment)
Piper Jaffray raised its price target on Sarepta Therapeutics (NASDAQ: SRPT) to $55.00 (from $50.00) while maintaining a Overweight rating.
Analyst Edward Tenthoff notes the positive Exon 53 data. The analyst further comments... More
September 6, 2017 8:42 AM EDT
Needham & Company analyst Chad Messer reiterated a Buy rating and $75 price target on Sarepta Therapeutics (NASDAQ: SRPT) after the company reported positive Phase I/II data for golodiresen, an exon 53 skipping therapy for Duchenne's muscular dystrophy (DMD).
Messer highlights s 2 significant positive... More
September 6, 2017 8:30 AM EDT
Baird analyst Brian Skorney reiterated an Outperform rating and $101 price target on Sarepta Therapeutics (NASDAQ: SRPT) following positive European Phase 1/2 study of SRP-4053.
Skorney said this strengthens the case for Sarepta's approach to exon expansion.
"With dystrophin expression exceeding that... More
